ReachMD CME
About
Available on
Community
2645 episodes
CME credits: 0.25 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/applying-sdm-to-personalize-treatment-discussions-on-recurrence-risk-reduction-in-patients-with-early-stage-melanoma/18105/ This Patient Clinician Connection CME activity, led by Dr. Meghan Mooradian, focuses on the use of adjuvant immunotherapy in early-stage melanoma. The activity aims to educate clinicians on the role of immunotherapy in reducing the risk of disease recurrence post-surgery, particularly in patients with resected stage IIB to III melanoma. Through patient clinical vignettes and audience education vignettes, participants will gain insights into patient-centered approaches, shared decision-making, and the management of immune-related adverse events associated with adjuvant immunotherapy, ultimately enhancing their ability to optimize treatment outcomes and patient care in this setting. =
CME credits: 0.50 Valid until: 25-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/extending-treatment-durability-with-next-generation-neovascular-amd-therapies/18067/ The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies, and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes. =
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-education-telling-is-not-teaching-and-listening-is-not-learning/17859/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-flush-another-colonoscopy-down-the-toilet/17860/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/screening-colonoscopy-in-2024-and-beyond/17855/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/quality-indicators-how-do-you-compare-part-1/17861/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/bowel-preparation-regimens-how-do-they-compare/17856/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-optimizing-patient-outcomes-in-multiple-sclerosis-strategies-for-early-intervention-to-address-progression-independent-of-relapse/16478/ New strategies for early intervention in multiple sclerosis (MS) are focusing on progression independent of relapse. These strategies include incorporation of high-efficacy disease modifying therapies in the early stages of MS coupled with effective management of treatment-related adverse events. Join Drs. Stephen Kreiger, Tirisham Gyang, and Augusto Miravalle for a lively, case-based exchange that will provide key ideas to take back into the clinic. =
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/new-and-emerging-agents/17863/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/quality-indicators-how-do-you-compare-part-2/17862/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/bowel-prep-hesitancy-whats-it-all-about/17857/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/another-inadequate-bowel-prep-it-may-not-be-the-patients-fault/17858/ In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.
CME credits: 0.25 Valid until: 14-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/cracking-the-crs-code-in-myeloma-insights-from-a-comprehensive-case-review/17876/ Bispecific antibodies are the newest immunotherapies approved for heavily pretreated relapsed/refractory myeloma, and they are shown to double response rates. Are you ready to use them in your practice? Join Drs. Costello and Lonial as they explore a case study that demonstrates how to select patients, prepare them for treatment, and effectively manage treatment-related side effects. =
CME credits: 1.00 Valid until: 09-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-latest-insights-into-rare-blood-disorders-diagnosis-and-treatment-strategies/16630/ Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it’s essential that healthcare providers possess up-to-date information about best practices and new developments in this area of medicine. In this activity, composed of 3 podcasts, an expert moderator will interview 3 expert faculty members about evidence-based guidelines for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura, developments in the diagnosis and treatment of cold agglutinin disease, and the challenges of achieving enduring remission in patients with immune thrombocytopenia. =
CME credits: 0.25 Valid until: 07-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/a-roadmap-to-safe-and-effective-bispecific-antibody-use-in-myeloma-mitigating-and-managing-adverse-events/17875/ Dive into the cutting-edge realm of bispecific antibodies for relapsed/refractory multiple myeloma with our experts, Dr. Caitlin Costello and Dr. Sagar Lonial. They explore the efficacy, safety, and practical integration of bispecific antibodies into clinical practice. Tune in to gain invaluable insights on optimizing patient care and navigating treatment-related adverse events to elevate your oncology practice. =
CME credits: 0.50 Valid until: 05-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/ultrasound-renal-denervation-interdisciplinary-approach-to-better-patient-outcomes/16625/ Dive into the realm of hypertension management through a chapterized expert interview CME activity on ultrasound renal denervation. In the first chapter, explore the significance of addressing hypertension. Delve into the sympathetic nervous system, ultrasound renal denervation mechanism, and clinical trial data in the second chapter. The third chapter offers dual perspectives on the role of the Hypertension Center, and walks learners through the development process for effective implementation. Gain comprehensive insights from leading experts, Drs. Naomi Fisher and Florian Rader, in this educational series. =
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/efficacy-data-for-bispecific-antibodies-in-rrmm/18058/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/considerations-for-dosing-bispecific-antibodies/18061/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/intracranial-activity-of-ros1-tkis/18157/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for + NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-acquired-tki-resistance-with-next-generation-ros1-tki-agents/18161/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for + NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-challenges-with-triple-class-or-penta-refractory-mm/18054/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-treatment-selection-for-ros1-rearranged-nsclc-patient-with-brain-metastases/18162/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for + NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/preventing-crs-and-neurotoxicities-related-to-bispecific-antibodies/18059/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/integrating-bispecific-antibodies-into-clinical-practice/18063/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/bispecific-antibodies-the-newest-immunotherapy-on-the-block-for-rrmm/18055/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/first-line-targeted-therapies-for-ros1-fusion-positive-lung-cancers/18155/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for + NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-guidelines-and-real-world-evidence-for-ros1-testing-in-nsclc/18154/ This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for + NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/approved-bispecific-antibodies-for-rrmm-review-of-the-pivotal-trials/18057/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/step-up-dosing-of-bispecific-antibodies-the-need-for-hospitalization/18062/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
CME credits: 1.00 Valid until: 01-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-infections-cytopenias-and-other-aes-related-to-bispecific-antibodies/18060/ "Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
